Study Details
Study to Test the long term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients with Symptoms of Overactive Bladder
Clinicaltrials.gov ID
Astellas Study ID
178-CL-049
EudraCT ID
2007-001452-39
Condition
Overactive Bladder Disease
Phase
Phase 3
Age
18 years - N/A
Sex
Female & Male
Product
N/A
Type
Interventional
Trial Dates
Apr 2008 - May 2010
Masking
Double (Participant, Investigator)
Enrollment number
2792
A Randomized, Double-Blind, Parallel Group, Active Controlled, Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) 50 mg qd and 100 mg qd in Subjects With Symptoms of Overactive Bladder
Study summary
Study documents
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for Study to Test the long term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients with Symptoms of Overactive Bladder? Contact us by filling our your information to the right and we’ll respond to you.